Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, six have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $56.3750.

IMCR has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Friday, July 17th. Zacks Research upgraded shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 5th. Morgan Stanley set a $43.00 target price on shares of Immunocore in a report on Friday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Finally, TD Cowen upgraded shares of Immunocore to a “strong-buy” rating in a research note on Monday.

Immunocore Stock Down 1.0%

IMCR stock opened at $36.75 on Friday. Immunocore has a fifty-two week low of $27.56 and a fifty-two week high of $40.71. The business’s 50-day moving average is $33.65 and its two-hundred day moving average is $31.57. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.47. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -99.32 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. As a group, analysts forecast that Immunocore will post 0.06 earnings per share for the current year.

Hedge Funds Weigh In On Immunocore

A number of institutional investors have recently bought and sold shares of IMCR. Leonteq Securities AG purchased a new position in Immunocore during the fourth quarter valued at $30,000. Harbour Investments Inc. increased its position in Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after buying an additional 388 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Immunocore in the fourth quarter worth about $47,000. Arax Advisory Partners raised its stake in shares of Immunocore by 302.9% in the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after buying an additional 1,042 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $61,000 after buying an additional 1,286 shares in the last quarter. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.